Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
COEP 
Coeptis Therapeutics Inc (COEP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: COEP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -52% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 61.03M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta -0.58 | 52 Weeks Range 2.31 - 14.70 | Updated Date 08/29/2025 |
52 Weeks Range 2.31 - 14.70 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.87 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate - | Actual -1.17 |
Profitability
Profit Margin - | Operating Margin (TTM) -2252.94% |
Management Effectiveness
Return on Assets (TTM) -98.25% | Return on Equity (TTM) -372.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 59370541 | Price to Sales(TTM) 231.55 |
Enterprise Value 59370541 | Price to Sales(TTM) 231.55 | ||
Enterprise Value to Revenue 225.27 | Enterprise Value to EBITDA -0.64 | Shares Outstanding 4820320 | Shares Floating 4198159 |
Shares Outstanding 4820320 | Shares Floating 4198159 | ||
Percent Insiders 13.49 | Percent Institutions 3.03 |
Upturn AI SWOT
Coeptis Therapeutics Inc
Company Overview
History and Background
Coeptis Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies. Founded in 2010, Coeptis has transitioned from a broader technology focus to concentrating on oncology and cell therapy related assets. Significant milestones include acquiring or licensing key technologies and initiating clinical trials.
Core Business Areas
- Oncology Therapeutics: Development of cancer therapies, including cell therapy approaches and traditional pharmaceutical compounds, focusing on unmet needs in hematological malignancies and solid tumors.
- Drug Development: Engaged in research, clinical development, and commercialization strategies for its product candidates.
Leadership and Structure
The company has a management team with expertise in pharmaceutical development, clinical trials, and commercialization. The organizational structure is typical of a small biotechnology company, with functional departments overseeing research, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- Consensi: FDA approved for lowering blood pressure. Revenue is not specifically broken out but is a revenue generating asset for the company. Competitors include generic antihypertensive medications from various pharmaceutical companies.
- CD38-GEAR-NK Cell Therapy: A cell therapy platform for oncology. Currently in preclinical development. Market share data not applicable at this stage. Competitors include cell therapy developers such as Caribou Biosciences and Nkarta.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and intense competition. The oncology segment is experiencing rapid growth due to an aging population and advancements in targeted therapies and immunotherapies.
Positioning
Coeptis Therapeutics is positioned as a niche player focused on innovative therapies. Their competitive advantage lies in their cell therapy platform and potentially synergistic combination therapies. However, they face stiff competition from larger pharmaceutical companies with greater resources.
Total Addressable Market (TAM)
The global oncology market is expected to reach $500 billion by 2028. Coeptis Therapeutics aims to capture a portion of this TAM through its novel cell therapy and drug development programs. Their positioning within the TAM is currently in the development and clinical trial stage, with potential for future market penetration upon successful commercialization.
Upturn SWOT Analysis
Strengths
- Innovative cell therapy platform (GEAR)
- Experienced management team
- Potential for synergistic combination therapies
- FDA Approved Drug (Consensi)
Weaknesses
- Limited financial resources
- Reliance on third-party manufacturers
- Early-stage development pipeline
- High risk of clinical trial failure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- FDA Fast track designation
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Patent infringements
Competitors and Market Share
Key Competitors
- CARB
- NKarta
- Gilead (GILD)
Competitive Landscape
Coeptis Therapeutics faces significant competition from larger, more established pharmaceutical companies with greater resources. Its competitive advantage lies in its novel technology and potentially synergistic combination therapies.
Major Acquisitions
Cellenkos Inc
- Year: 2023
- Acquisition Price (USD millions): 6.2
- Strategic Rationale: Acquisition of Cellenkos enhances Coeptis's cell therapy platform.
Growth Trajectory and Initiatives
Historical Growth: Coeptis Therapeutics' historical growth has been characterized by strategic acquisitions and development of its technology platforms.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals. Analyst estimates vary widely due to the inherent uncertainties in drug development.
Recent Initiatives: Recent initiatives include advancing the CD38-GEAR-NK cell therapy program and exploring strategic partnerships.
Summary
Coeptis Therapeutics is a small pharmaceutical company with a focus on cell therapy and oncology. Its strengths lie in its innovative technology and experienced management team, but it faces challenges due to its limited financial resources and early-stage development pipeline. The company's future success depends on positive clinical trial results and strategic partnerships. The recent acquisition of Cellenkos could add value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Press releases
- Analyst reports (where available)
- Company Investor Relations Site
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Coeptis Therapeutics Inc
Exchange NASDAQ | Headquaters Wexford, PA, United States | ||
IPO Launch date 2020-12-17 | Co-Founder, Chairman of the Board, CEO & President Mr. David Mehalick | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://coeptistx.com |
Full time employees 5 | Website https://coeptistx.com | ||
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy technology. Its product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological and solid tumors. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.